Exendin-4 for Parkinson's disease.
| Autor: | Esparza-Salazar FJ; Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA., Lezama-Toledo AR; Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA., Rivera-Monroy G; Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA., Borlongan CV; Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Brain circulation [Brain Circ] 2021 Mar 30; Vol. 7 (1), pp. 41-43. Date of Electronic Publication: 2021 Mar 30 (Print Publication: 2021). |
| DOI: | 10.4103/bc.bc_21_21 |
| Abstrakt: | This review article discusses the preclinical evidence and clinical trials testing the use of a peptide agonist of the glucagon-like peptide (GLP) receptor that promotes insulin secretion in the animal models of and patient with Parkinson's disease (PD). In particular, we focus on the therapeutic effects of the GLP receptor agonist exendin-4, also called exenatide, in PD. The ultimate goal of this article is to provide a critical assessment of the laboratory and clinical data toward guiding the translation of exendin-4 as a clinically relevant therapeutic for PD. Competing Interests: Prof. Cesario V. Borlongan is Associate Editor of Brain Circulation. (Copyright: © 2021 Brain Circulation.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|